Skip to content

Study · Not a test of the peptide alone · 2023

10 results

Spinal cord injury induced exacerbation of Alzheimer's disease like pathophysiology is reduced by topical application of nanowired cerebrolysin with monoclonal antibodies to amyloid beta peptide, p-tau and tumor necrosis factor alpha.

Sharma A, Feng L, Muresanu DF, Tian ZR, Lafuente JV, Buzoianu AD, Nozari A, Wiklund L, Sharma HS

International review of neurobiology26 Sept 2023

PMID37833015 (opens in a new tab)DOI10.1016/bs.irn.2023.05.011 (opens in a new tab)PepBankPUB-37833015
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 01AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome

    In a spinal cord injury model, nanowired Cerebrolysin with antibodies attenuated amyloid beta deposition in brain and spinal cord.

    In plain wordsIn an animal model, Cerebrolysin with antibodies reduced amyloid beta deposits in the brain and spinal cord.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseAmyloid beta deposition
    Study

    n: not reported in source

    Focal spinal cord injury
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Repeated nanowired delivery of cerebrolysin topically over the traumatized segment repeatedly together with monoclonal antibodies (mAb) to amyloid beta peptide (AβP), p-tau and TNF-α significantly attenuated amyloid beta peptide, p-tau deposition

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  2. 02AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome

    In a spinal cord injury model, nanowired Cerebrolysin with antibodies attenuated phosphorylated tau deposition.

    In plain wordsIn an animal model, Cerebrolysin with antibodies reduced phosphorylated tau deposits.

    Peptide
    Cerebrolysin
    Outcome
    DecreasePhosphorylated tau deposition
    Study

    n: not reported in source

    Focal spinal cord injury
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Repeated nanowired delivery of cerebrolysin topically over the traumatized segment repeatedly together with monoclonal antibodies (mAb) to amyloid beta peptide (AβP), p-tau and TNF-α significantly attenuated amyloid beta peptide, p-tau deposition

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  3. 03AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Mechanism

    In a spinal cord injury model, nanowired Cerebrolysin with antibodies reduced Iba1 levels in brain and spinal cord.

    In plain wordsIn an animal model, Cerebrolysin with antibodies reduced Iba1 levels in the brain and spinal cord.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseIba1 levels
    Study

    n: not reported in source

    Focal spinal cord injury
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    and reduces Iba1, CD68 and TNF-α levels in the brain and spinal cord
    1 context sentence
    Summary · context
    Repeated nanowired delivery of cerebrolysin topically over the traumatized segment repeatedly together with monoclonal antibodies (mAb) to amyloid beta peptide (AβP), p-tau and TNF-α significantly attenuated amyloid beta peptide, p-tau deposition

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  4. 04AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Mechanism

    In a spinal cord injury model, nanowired Cerebrolysin with antibodies reduced CD68 levels in brain and spinal cord.

    In plain wordsIn an animal model, Cerebrolysin with antibodies reduced CD68 levels in the brain and spinal cord.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseCD68 levels
    Study

    n: not reported in source

    Focal spinal cord injury
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    and reduces Iba1, CD68 and TNF-α levels in the brain and spinal cord
    1 context sentence
    Summary · context
    Repeated nanowired delivery of cerebrolysin topically over the traumatized segment repeatedly together with monoclonal antibodies (mAb) to amyloid beta peptide (AβP), p-tau and TNF-α significantly attenuated amyloid beta peptide, p-tau deposition

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  5. 05AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Mechanism

    In a spinal cord injury model, nanowired Cerebrolysin with antibodies reduced TNF-alpha levels in brain and spinal cord.

    In plain wordsIn an animal model, Cerebrolysin with antibodies reduced TNF-alpha levels in the brain and spinal cord.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseTNF-alpha levels
    Study

    n: not reported in source

    Focal spinal cord injury
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    and reduces Iba1, CD68 and TNF-α levels in the brain and spinal cord
    1 context sentence
    Summary · context
    Repeated nanowired delivery of cerebrolysin topically over the traumatized segment repeatedly together with monoclonal antibodies (mAb) to amyloid beta peptide (AβP), p-tau and TNF-α significantly attenuated amyloid beta peptide, p-tau deposition

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  6. 06AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome

    In a spinal cord injury model, nanowired Cerebrolysin with antibodies blocked blood-brain barrier disruption.

    In plain wordsIn an animal model, Cerebrolysin with antibodies blocked blood-brain barrier disruption.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseBlood-brain barrier disruption
    Study

    n: not reported in source

    Focal spinal cord injury
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    along with blockade of BBB and BSCB, reduction in blood flow, edema formation and cell injury.
    1 context sentence
    Summary · context
    Repeated nanowired delivery of cerebrolysin topically over the traumatized segment repeatedly together with monoclonal antibodies (mAb) to amyloid beta peptide (AβP), p-tau and TNF-α significantly attenuated amyloid beta peptide, p-tau deposition

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  7. 07AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome

    In a spinal cord injury model, nanowired Cerebrolysin with antibodies blocked blood-spinal cord barrier disruption.

    In plain wordsIn an animal model, Cerebrolysin with antibodies blocked blood-spinal cord barrier disruption.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseBlood-spinal cord barrier disruption
    Study

    n: not reported in source

    Focal spinal cord injury
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    along with blockade of BBB and BSCB, reduction in blood flow, edema formation and cell injury.
    1 context sentence
    Summary · context
    Repeated nanowired delivery of cerebrolysin topically over the traumatized segment repeatedly together with monoclonal antibodies (mAb) to amyloid beta peptide (AβP), p-tau and TNF-α significantly attenuated amyloid beta peptide, p-tau deposition

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  8. 08AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome

    In a spinal cord injury model, the abstract reports reduced blood flow with nanowired Cerebrolysin and antibodies.

    In plain wordsIn an animal model, the abstract reports reduced blood flow with Cerebrolysin and antibodies.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseBlood flow
    Study

    n: not reported in source

    Focal spinal cord injury
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    along with blockade of BBB and BSCB, reduction in blood flow, edema formation and cell injury.
    1 context sentence
    Summary · context
    Repeated nanowired delivery of cerebrolysin topically over the traumatized segment repeatedly together with monoclonal antibodies (mAb) to amyloid beta peptide (AβP), p-tau and TNF-α significantly attenuated amyloid beta peptide, p-tau deposition

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  9. 09AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome

    In a spinal cord injury model, nanowired Cerebrolysin with antibodies reduced edema formation.

    In plain wordsIn an animal model, Cerebrolysin with antibodies reduced swelling.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseEdema formation
    Study

    n: not reported in source

    Focal spinal cord injury
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    along with blockade of BBB and BSCB, reduction in blood flow, edema formation and cell injury.
    1 context sentence
    Summary · context
    Repeated nanowired delivery of cerebrolysin topically over the traumatized segment repeatedly together with monoclonal antibodies (mAb) to amyloid beta peptide (AβP), p-tau and TNF-α significantly attenuated amyloid beta peptide, p-tau deposition

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  10. 10AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome

    In a spinal cord injury model, nanowired Cerebrolysin with antibodies reduced cell injury.

    In plain wordsIn an animal model, Cerebrolysin with antibodies reduced cell injury.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseCell injury
    Study

    n: not reported in source

    Focal spinal cord injury
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    along with blockade of BBB and BSCB, reduction in blood flow, edema formation and cell injury.
    1 context sentence
    Summary · context
    Repeated nanowired delivery of cerebrolysin topically over the traumatized segment repeatedly together with monoclonal antibodies (mAb) to amyloid beta peptide (AβP), p-tau and TNF-α significantly attenuated amyloid beta peptide, p-tau deposition

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.